行情

PTI

PTI

Proteostasis
NASDAQ

实时行情|Nasdaq Last Sale

1.730
+0.030
+1.76%
交易中 13:14 01/28 EST
开盘
1.700
昨收
1.700
最高
1.740
最低
1.681
成交量
37.42万
成交额
--
52周最高
4.720
52周最低
0.6100
市值
8,845.31万
市盈率(TTM)
-1.3442
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PTI 新闻

  • Proteostasis Therapeutics Announces Keystone Symposia Presentation of Organoid Study from More than 300 Adult CF Patients
  • PR Newswire.6天前
  • Proteostasis Therapeutics Option Alert: Fri $1 Calls Sweep (5) near the Ask: 1600 @ $0.95 vs 2418 OI; Ref=$1.95
  • Benzinga.01/14 15:14
  • DDD, NVTA among premarket gainers
  • Seeking Alpha - Article.01/13 14:27
  • Proteostasis Therapeutics Regulatory Update Following Scientific Advice Meeting with MHRA
  • PR Newswire.01/13 13:00

更多

所属板块

生物技术和医学研究
+1.18%
制药与医学研究
+0.56%

热门股票

名称
价格
涨跌幅

PTI 简况

Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of novel therapeutics to treat cystic fibrosis (CF), and other diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. The Company focuses on identifying therapies that restore protein function. The Company’s CF focused pipeline consists of novel CFTR modulators including correctors, potentiators and amplifiers. The Company’s clinical developments include PTI-801, a third generation CFTR corrector, PTI-808, a CFTR potentiator, and PTI-428, a CFTR amplifier.
展开

Webull提供Proteostasis Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。